Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: An alternative hypothesis [7]

AIDS

Volumn 16, Issue 3, 2002, Pages 506-507

  Qazi, Nadeem A ^a   Morlese, John F ^a   King, D Michael ^a   Ahmad, Rizvana S ^a   Gazzard, Brian G ^a   Nelson, Mark R ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ;

CLINICAL ARTICLE; CONTROLLED STUDY; ECHOMAMMOGRAPHY; GYNECOMASTIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; LETTER; LIPODYSTROPHY; PATHOGENESIS; PRIORITY JOURNAL; SERODIAGNOSIS;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; GYNECOMASTIA; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; OXAZINES; RNA, VIRAL;

EID: 0037084025     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200202150-00033     Document Type: Letter

References (7)

1. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz
2. True gynaecomastia is not a form of lipodystrophy and can occur with all classes of antiretrovirals
3. Ultrasound mammography for male breast enlargements
4. True gynaecomastia, another manifestation of immune reconstitution disease?
5. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: Impact of highly active antiretroviral therapy
6. Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2
7. The regulation of aromatase activity in breast fibroblasts: The role of interleukin-6 and prostaglandin E2